» Authors » Shlomi Lazar

Shlomi Lazar

Explore the profile of Shlomi Lazar including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 35
Citations 403
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Koshrovski-Michael S, Ajamil D, Dey P, Kleiner R, Tevet S, Epshtein Y, et al.
Sci Adv . 2024 Dec; 10(50):eadr4762. PMID: 39671487
Combined therapies in cancer treatment aim to enhance antitumor activity. However, delivering multiple small molecules imposes challenges, as different drugs have distinct pharmacokinetic profiles and tumor penetration abilities, affecting their...
2.
Lazar S, Neufeld-Cohen A, Egoz I, Baranes S, Gez R, Glick P, et al.
Toxicol Appl Pharmacol . 2024 Feb; 484:116870. PMID: 38395364
The development of refractory status epilepticus (SE) following sarin intoxication presents a therapeutic challenge. Here, we evaluated the efficacy of delayed combined double or triple treatment in reducing abnormal epileptiform...
3.
Gal Y, Sapoznikov A, Lazar S, Shoseyov D, Aftalion M, Gutman H, et al.
Toxins (Basel) . 2024 Feb; 16(2). PMID: 38393180
Ricin, a highly potent plant-derived toxin, is considered a potential bioterrorism weapon due to its pronounced toxicity, high availability, and ease of preparation. Acute damage following pulmonary ricinosis is characterized...
4.
Milrot E, Lazar S, Schuster O, Makdasi E, Shmaya S, Yahalom-Ronen Y, et al.
Viruses . 2022 Dec; 14(12). PMID: 36560832
Fundamental key processes in viral infection cycles generally occur in distinct cellular sites where both viral and host factors accumulate and interact. These sites are usually termed viral replication organelles,...
5.
Cohen N, Vagima Y, Mouhadeb O, Toister E, Gutman H, Lazar S, et al.
Front Bioeng Biotechnol . 2022 Aug; 10:905557. PMID: 36017344
Recent advances in the field of cell therapy have proposed new solutions for tissue repair and regeneration using various cell delivery approaches. Here we studied a novel topical delivery system...
6.
Tamir H, Melamed S, Erez N, Politi B, Yahalom-Ronen Y, Achdout H, et al.
Viruses . 2022 Feb; 14(2). PMID: 35215785
SARS-CoV-2, a member of the coronavirus family, is the causative agent of the COVID-19 pandemic. Currently, there is still an urgent need in developing an efficient therapeutic intervention. In this...
7.
Madar-Balakirski N, Rosner A, Melamed S, Politi B, Steiner M, Tamir H, et al.
Arch Toxicol . 2022 Jan; 96(3):859-875. PMID: 35032184
rVSV-ΔG-SARS-CoV-2-S is a clinical stage (Phase 2) replication competent recombinant vaccine against SARS-CoV-2. To evaluate the safety profile of the vaccine, a series of non-clinical safety, immunogenicity and efficacy studies...
8.
Blanca M, Shifrovitch A, Dachir S, Lazar S, Elgarisi M, Prihed H, et al.
Arch Toxicol . 2021 May; 95(7):2403-2412. PMID: 34032868
Long-term retrospective monitoring of exposure to organophosphorus nerve agents is challenging. We recently developed two highly sensitive analytical methods for regenerated sarin (GB) nerve agent in blood and its primary...
9.
Amitai G, Plotnikov A, Chapman S, Lazar S, Gez R, Loewenthal D, et al.
Commun Biol . 2021 May; 4(1):573. PMID: 33990679
Government-sanctioned use of nerve agents (NA) has escalated dramatically in recent years. Oxime reactivators of organophosphate (OP)-inhibited acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) serve as antidotes toward poisoning by OPNAs. The...
10.
Falach R, Bar-On L, Lazar S, Kadar T, Mazor O, Aftalion M, et al.
JCI Insight . 2021 May; 6(12). PMID: 33974566
Mice are normally unaffected by SARS coronavirus 2 (SARS-CoV-2) infection since the virus does not bind effectively to the murine version of the angiotensin-converting enzyme 2 (ACE2) receptor molecule. Here,...